Subscribe
nobeastsofierce
nobeastsofierce / Shutterstock.com
6 August 2020BiotechnologyRory O'Neill

LSPN Connect: micro-managing with Pendulum Therapeutics

With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
LSPN Connect: MPP chief wants COVID-19 role
26 June 2020   The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
LSPN Connect: MPP chief wants COVID-19 role
26 June 2020   The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.

More on this story

Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
LSPN Connect: MPP chief wants COVID-19 role
26 June 2020   The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott